ReviewJournal of cellular and molecular medicine2015
Analysis of different HER-2 mutations in breast cancer progression and drug resistance.
Review in Journal of cellular and molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer.World journal of surgical oncology · 2026Article
- Comprehensive Molecular Docking and Molecular Dynamics Reveal Inhibitors of HER2 L755S, T798I, and T798M based on a Large Database of Curcumin Derivatives.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Causal relationships between immune cell traits and HER2 subtypes in breast cancer: a Mendelian randomization study.Discover oncology · 2025Article
- Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype.Cell reports. Medicine · 2025Article
- The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Recent Advances and Mechanisms of Phage-Based Therapies in Cancer Treatment.International journal of molecular sciences · 2024Review
- HER2 mutation as an emerging target in advanced breast cancer.Cancer science · 2024Review
- Promising predictive molecular biomarkers for cervical cancer (Review).International journal of molecular medicine · 2024Review
- The prognostic genes model of breast cancer drug resistance based on single-cell sequencing analysis and transcriptome analysis.Clinical and experimental medicine · 2024Article
- Dynamic changes in tumor profiling reveal intra- and inter-tumoral heterogeneity focused on an uncharacterized HER2 mutation: a case report of a young breast cancer patient.Frontiers in oncology · 2024Article
- Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022Article
- ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells.International journal of molecular sciences · 2022Article
- Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine.Cancers · 2022Review
- Value of CT-Based Radiomics in Predicating the Efficacy of Anti-HER2 Therapy for Patients With Liver Metastases From Breast Cancer.Frontiers in oncology · 2022Article
- A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.Journal of pharmacokinetics and pharmacodynamics · 2021Article
- Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma.Pharmaceutics · 2021Article
- Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells.OncoTargets and therapy · 2021Article
- Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases.Nature structural & molecular biology · 2020Article
- Somatic Mutations inJournal of oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies over the last two decades have identified that amplified human epidermal growth factor receptor (HER-2; c-erbB-2, neu) and its overexpression have been frequently implicated in the carcinogenesis and prognosis in a variety of solid tumours, especially breast cancer. Lots of painstaking efforts were invested on the HER-2 targeted agents, and significantly improved outcome and prolonged the survival of patients. However, some patients classified as 'HER-2-positive' would be still resistant to the anti-HER-2 therapy. Various mechanisms of drug resistance have been illustrated and the alteration of HER-2 was considered as a crucial mechanism. However, systematic researches in regard to the HER-2 mutations and variants are still inadequate. Notably, the alterations of HER-2 play an important role in drug resistance, but also have a potential association with the cancer risk. In this review, we summarize the possible mutations and focus on HER-2 variants' role in breast cancer tumourigenesis. Additionally, the alteration of HER-2, as a potential mechanism of resistance to trastuzumab, is discussed here. We hope that HER-2 related activating mutations could potentially offer more therapeutic opportunities to a broader range of patients than previously classified as HER-2 overexpressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.